BIIB BIIB

Biogen Stock Price

217.58
0.00 (0.0%)
217.58
Volume 0
Bid Price 216.51
Ask Price 217.50
News -
Day High

Low
187.16

52 Week Range

High
351.86

Day Low
Company Name Stock Ticker Symbol Market Type
Biogen Inc BIIB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 217.58 06:21:41
Open Price Low Price High Price Close Price Prev Close
217.58
Trades Volume Avg Volume 52 Week Range
0 0 - 187.16 - 351.86
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 217.58 USD

Period:

Draw Mode:

Biogen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 31.57B 145.11M 128.43M $ 10.98B $ 1.69B 10.40 15.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 15.73k 1.40%

more financials information »

Biogen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BIIB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week221.22222.82216.61219.94636,933-3.64-1.65%
1 Month208.27222.82204.175214.84830,1049.314.47%
3 Months202.98222.82188.535208.911,000,29714.607.19%
6 Months209.21225.50187.16207.001,057,6148.374.0%
1 Year349.43351.86187.16234.641,192,768-131.85-37.73%
3 Years233.37468.2499187.16277.131,496,327-15.79-6.77%
5 Years283.31468.2499187.16282.791,513,371-65.73-23.2%

Biogen Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.


Your Recent History
NASDAQ
BIIB
Biogen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now